These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 11747684)

  • 21. Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis.
    del Puente A; Scognamiglio A; Itto E; Ferrara G; Oriente P
    J Rheumatol; 2000 Aug; 27(8):1980-3. PubMed ID: 10955341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends and determinants of antiresorptive drug use for osteoporosis among elderly women.
    Perreault S; Dragomir A; Desgagné A; Blais L; Rossignol M; Blouin J; Moride Y; Ste-Marie LG; Fernandès JC
    Pharmacoepidemiol Drug Saf; 2005 Oct; 14(10):685-95. PubMed ID: 15645517
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of estrogen therapy on bone mass in postmenopausal women with osteopenia].
    Insua A; Negri A; Zanchetta JR
    Medicina (B Aires); 1995; 55(5 Pt 1):408-14. PubMed ID: 8728770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of raloxifene after discontinuation of long-term alendronate treatment of postmenopausal osteoporosis.
    Michalská D; Stepan JJ; Basson BR; Pavo I
    J Clin Endocrinol Metab; 2006 Mar; 91(3):870-7. PubMed ID: 16352692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of alendronate on bone density in men with primary and secondary osteoporosis.
    Ho YV; Frauman AG; Thomson W; Seeman E
    Osteoporos Int; 2000; 11(2):98-101. PubMed ID: 10793867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention and treatment of osteoporosis in women with breast cancer.
    Mincey BA; Moraghan TJ; Perez EA
    Mayo Clin Proc; 2000 Aug; 75(8):821-9. PubMed ID: 10943237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of teriparatide [rhPTH(1-34)] on BMD when given to postmenopausal women receiving hormone replacement therapy.
    Ste-Marie LG; Schwartz SL; Hossain A; Desaiah D; Gaich GA
    J Bone Miner Res; 2006 Feb; 21(2):283-91. PubMed ID: 16418784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alendronate for the prevention of bone mineral loss during gonadotropin-releasing hormone agonist therapy.
    Ripps BA; VanGilder K; Minhas B; Welford M; Mamish Z
    J Reprod Med; 2003 Oct; 48(10):761-6. PubMed ID: 14619641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate.
    Watts NB; Jenkins DK; Visor JM; Casal DC; Geusens P
    Osteoporos Int; 2001; 12(4):279-88. PubMed ID: 11420777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial.
    Lindsay R; Cosman F; Lobo RA; Walsh BW; Harris ST; Reagan JE; Liss CL; Melton ME; Byrnes CA
    J Clin Endocrinol Metab; 1999 Sep; 84(9):3076-81. PubMed ID: 10487668
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative efficacy and safety study of etidronate and alendronate in postmenopausal osteoporosis. effect of adding hormone replacement therapy.
    Cortet B; Béra-Louville A; Gauthier P; Gauthier A; Marchandise X; Delcambre B
    Joint Bone Spine; 2001 Oct; 68(5):410-5. PubMed ID: 11707007
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of alendronate and hormone replacement therapy, alone or in combination, on bone mass in postmenopausal women with osteoporosis: a prospective, randomized study.
    Tiraş MB; Noyan V; Yildiz A; Yildirim M; Daya S
    Hum Reprod; 2000 Oct; 15(10):2087-92. PubMed ID: 11006178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of hormone replacement, alendronate, or combination therapy on hip structural geometry: a 3-year, double-blind, placebo-controlled clinical trial.
    Greenspan SL; Beck TJ; Resnick NM; Bhattacharya R; Parker RA
    J Bone Miner Res; 2005 Sep; 20(9):1525-32. PubMed ID: 16059624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A review of combination regimens for osteoporosis--prevention and treatment.
    Miller E; Kalin MF
    Int J Fertil Womens Med; 2002; 47(5):198-204. PubMed ID: 12469706
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis.
    Hernández E; Valera R; Alonzo E; Bajares-Lilue M; Carlini R; Capriles F; Martinis R; Bellorin-Font E; Weisinger JR
    Kidney Int; 2003 Jun; 63(6):2269-74. PubMed ID: 12753317
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.
    Sambrook PN; Geusens P; Ribot C; Solimano JA; Ferrer-Barriendos J; Gaines K; Verbruggen N; Melton ME
    J Intern Med; 2004 Apr; 255(4):503-11. PubMed ID: 15049885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benefit period using alendronate to increase bone mineral density in women with osteoporosis?
    Ozdemir F; Rodoplu M
    Chin Med J (Engl); 2005 Mar; 118(5):383-90. PubMed ID: 15780207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Month 3 and month 6 measurements of bone mineral density predict the annual outcome in postmenopausal women with osteoporosis in whom alendronate was added to long-term HRT.
    Pines A; Eckstein N; Kopernik G; Ayalon D; Comaneshter D; Frenkel Y
    Maturitas; 2003 Apr; 44(4):287-92. PubMed ID: 12697369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.